After our promising results with #tambjamine family drugs at #EcopolTech's biotechnological polymers division we continue developing new pH-triggered #antitumor #nanomedicines to treat non-small cell lung cancer (#NSCLC) using the benchmark drugs #cisplatin and #irinotecan.
Thanks to our collaborators from Hospital Universitari de Bellvitge, Universidad de Burgos and Vall d’Hebron Institute of Research (VHIR).
Our goal is to have our new nano candidate ready to move into #ClinicalPhase by 2023.
More news to come soon.
Request more information at info(at)ecopoltech.com